Stay updated on Pralsetinib in RET+ Cancer Clinical Trial

Sign up to get notified when there's something new on the Pralsetinib in RET+ Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pralsetinib in RET+ Cancer Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    Added bibliographic entry: Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer, J Clin Oncol, 2026 (online ahead of print).
    Difference
    0.0%
    Check dated 2026-04-04T05:51:32.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    Added Medullary thyroid carcinoma to the conditions list. Added a Resources section linking to the Genetic and Rare Diseases Information Center.
    Difference
    0.1%
    Check dated 2026-03-28T01:52:45.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    Revision updated from v3.4.3 to v3.5.0 on the page.
    Difference
    0.0%
    Check dated 2026-03-20T22:24:38.000Z thumbnail image
  4. Check
    27 days ago
    No Change Detected
  5. Check
    34 days ago
    Change Detected
    Summary
    Page revision updated from v3.4.2 to v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-06T17:54:33.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    Revision: v3.4.2 is shown on the page, replacing v3.4.1. The content related to the study remains unchanged.
    Difference
    0.0%
    Check dated 2026-02-13T12:48:53.000Z thumbnail image
  7. Check
    63 days ago
    Change Detected
    Summary
    Revision updated from v3.4.0 to v3.4.1; no user-visible changes to page content were detected. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-06T09:14:55.000Z thumbnail image

Stay in the know with updates to Pralsetinib in RET+ Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pralsetinib in RET+ Cancer Clinical Trial page.